Johnson & Johnson Reports 2016 Third-Quarter Results:

Go back to Johnson & Johnson Reports 2016 Third-Quarter Results:

Johnson & Johnson (JNJ) Tops Q3 EPS by 3c; Boosts FY16 Outlook

October 18, 2016 6:41 AM EDT

Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $1.68, $0.03 better than the analyst estimate of $1.65. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $17.71 billion.

Xarelto revenue $529 million, versus $564 million expected.

Imbruvica revenue $349 million, estimate at $313... More